(Q46753346)

24 December 2017

title

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates (English)

1 reference

24 December 2017

1 reference

4

1 reference

24 December 2017

Ayalew Tefferi

1

object named as

Ayalew Tefferi

1 reference

24 December 2017

3

Susan M Schwager

1 reference

24 December 2017

author name string

Terra L Lasho

2

1 reference

24 December 2017

Ruben A Mesa

5

1 reference

24 December 2017

Chin-Yang Li

6

1 reference

24 December 2017

Martha Wadleigh

7

1 reference

24 December 2017

D Gary Gilliland

8

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

24 December 2017

British Journal of Haematology

published in

1 reference

24 December 2017

volume

131

1 reference

24 December 2017

issue

3

1 reference

24 December 2017

page(s)

320-328

1 reference

24 December 2017

The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

PRL activates the cyclin D1 promoter via the Jak2/Stat pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Increased expression of the INK4a/ARF locus in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

On the molecular origins of the chronic myeloproliferative disorders: it all makes sense

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

STAT3 is constitutively active in some patients with Polycythemia rubra vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

JAKing up hematopoietic proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Expression of Bcl-x in erythroid precursors from patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

Identification of an acquired JAK2 mutation in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05776.X

10.1111/J.1365-2141.2005.05776.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017